The HRT Warning Label Changed. Here's What It Means for You.

For more than 20 years, menopause hormone therapy came with one of the scariest labels in medicine: a black box warning about heart disease, breast cancer, stroke and dementia. A whole generation of women grew up believing HRT was dangerous.

In November 2025, the FDA started taking most of that box away. Here's what changed, what didn't, and what it means for you.

How We Got Here

In July 2002, the Women's Health Initiative (WHI) published results from a trial of 16,608 women aged 50 to 79 taking estrogen plus progestin. It was stopped early after about five years. For every 10,000 women per year, the hormone group had 8 more invasive breast cancers, 8 more strokes and 7 more heart events, along with 6 fewer colorectal cancers and 5 fewer hip fractures.

The fallout was huge. According to the AP, more than 1 in 4 U.S. women took hormone therapy in the 1990s, and prescriptions plummeted after 2002. One study of U.S. doctor visits found hormone therapy use fell 52% from 2001 to 2009.

The nuance that got lost: the average WHI participant was about 63, more than a decade past the typical age of menopause.

What the FDA Changed

On November 10, 2025, the FDA asked companies to update their labels. For all menopause hormone therapy products, including vaginal creams, tablets and rings, the boxed warning will no longer include:

• Cardiovascular disease

• Breast cancer

• Probable dementia (removed from the label entirely)

• The advice to use "the lowest effective dose for the shortest amount of time"

The FDA's new labeled recommendation is to start systemic HRT before age 60 or within 10 years of menopause.

What Didn't Change

• The endometrial cancer boxed warning stays on systemic estrogen-alone products. Estrogen on its own can thicken the uterine lining, which is why women with a uterus usually also take a progestogen.

• Heart disease and breast cancer risks are still on the label. The FDA moved them out of the box into the regular warnings section. It didn't erase them.

Where Things Stand Now

On February 12, 2026, the FDA approved updated labels for the first six products, including the vaginal ring Estring, and said 29 companies had submitted changes. More updates have been expected since. If your prescription still shows the old box, that's likely because its label hasn't been updated yet, not because your medication is different.

What the Experts Say

The Menopause Society agreed with removing the boxed warning on low-dose vaginal estrogen, calling it "a safe and effective therapy for a condition that affects most menopausal women." It also cautioned that "systemic estrogen still comes with potential risks in certain individuals," especially for women who start later.

Its 2022 position statement says that for women under 60 or within 10 years of menopause without reasons to avoid it, benefits generally outweigh risks for treating hot flashes and preventing bone loss.

Not everyone applauded the process. Some experts criticized the FDA for skipping its usual advisory committee review. Harvard's JoAnn Manson told the AP that the evidence for broad health benefits is less conclusive than FDA leaders suggested, though she called removing a "one size fits all" warning a good step.

Side Effects: What to Know

A lighter label doesn't mean zero risk. The FDA kept these in the label's warnings:

• Cardiovascular risks, including blood clots and stroke, which the Menopause Society says are higher when women start therapy later or further from menopause

• Breast cancer risk, discussed in the warnings section

• Endometrial cancer with estrogen alone if you have a uterus

When Should You Be Concerned?

Get medical care right away if you're on HRT and notice:

• Chest pain, sudden shortness of breath or coughing up blood

• Pain, swelling or warmth in one leg

• Sudden severe headache, vision changes, slurred speech, or weakness on one side

• Unexpected vaginal bleeding after menopause

• A new breast lump

What We Know vs. What We Don't

We know: the FDA has removed the broad boxed warnings, starting before 60 or within 10 years of menopause is the recommended window, and low-dose vaginal estrogen got the strongest expert support.

We don't know: how many products have updated labels as of today, and experts still debate how much hormone therapy protects the heart or brain long-term.

The Bottom Line

If you dismissed HRT years ago because of the warning label, it's worth a fresh conversation with your doctor. Bring your personal and family history, your symptoms and your questions. The decision is still individual, and now it's yours to make with better information.

Your turn: Did the old HRT warning shape your decisions? Would this change make you reconsider?

This post is for educational purposes only and is not medical advice.

Sources

• U.S. FDA. HHS Advances Women's Health, Removes Misleading FDA Warnings on Hormone Replacement Therapy. Nov 10, 2025.

• U.S. FDA. FDA Requests Labeling Changes for Menopausal Hormone Therapies.

• U.S. FDA. FDA approves labeling changes to menopausal hormone therapy products. Feb 12, 2026.

• U.S. FDA. Hormone Replacement Therapies Can Help Women with Bothersome Menopausal Symptoms. Feb 2026.

• Writing Group for the WHI Investigators. Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women. JAMA, 2002.

• Tsai SA, et al. Trends in Menopausal Hormone Therapy Use of U.S. Office-Based Physicians, 2000–2009. Menopause, 2011.

• AP via OPB. The FDA removes a long-standing warning from hormone-based menopause drugs. Nov 10, 2025.

• The Menopause Society. Comments on the FDA Announcement on Hormone Therapy. Nov 2025.

• The North American Menopause Society. The 2022 hormone therapy position statement.